1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Chronic Disease Market Trends
  5. > Generic Drug Opportunity Assessment : Dabigatran (Pradaxa)

Generic Drug Opportunity Assessment : Dabigatran (Pradaxa)

  • January 2014
  • -
  • Greystone Research Associates

Greystone Research Associates has identified a branded drug that represents an attractive opportunity for generic drug companies. Details of our findings are contained in an insightful assessment.

Overview

Pradaxa (dabigatran etexilate) is a novel reversible oral direct thrombin inhibitor that blocks the activity of thrombin, the central enzyme in clot formation. It is approved for the primary prevention of venous thrombo-embolism (VTE) in adults who have undergone elective total hip or knee replacement surgery and was the first new anticoagulation therapy in half a century to be approved for the prevention of stroke and systemic embolism for adult patients with non-valvular atrial fibrillation who are at risk of stroke.

The Market
Atrial fibrillation (AF) increases the risk of stroke. The degree of increase can be substantial, depending on the presence of additional risk factors (such as high blood pressure). Atrial fibrillation may be treated with medications to either slow the heart rate to a normal range (rate control) or revert the heart rhythm to normal (rhythm control). The prevalence of AF in a population increases with age, with 8% of people over 80 having AF. Chronic AF leads to a small increase in the risk of death.
Nonvalvular atrial fibrillation is AF in the absence of rheumatic mitral valve disease, a prosthetic heart valve, or mitral valve repair. Apixaban (Eliquis), is one of a group of novel oral anticoagulants (NOACs) that are more convenient, and are at least equally effective and safer (regarding bleeding complications) for stroke prevention compared with vitamin K antagonists (VKAs).

Report Highlights

Pradaxa – The Brand
Dabigatran – The Market
Dabigatran – The Opportunity
Manufacturing and Sourcing
Pradaxa Patents and Exclusivity
Therapeutic Class P4 Certifications
Generic First-to-File Revenue Opportunity
Business Risk Assessment
First-to-File – Probabilistic Scenario

Table Of Contents

Generic Drug Opportunity Assessment : Dabigatran (Pradaxa)

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Amrita

+1 718 303 2019

Purchase Reports From Reputable Market Research Publishers
Vascular Graft Market: By Raw Material (Polyester, Polytetrafluoroethylene, Others); By Product (Hemodialysis Access, Endovascular Stent, Others); By Application (Cardiovascular Diseases, Cardiac Aneurysm, Others) & By Region-Forecast (2016-2022)

Vascular Graft Market: By Raw Material (Polyester, Polytetrafluoroethylene, Others); By Product (Hemodialysis Access, Endovascular Stent, Others); By Application (Cardiovascular Diseases, Cardiac Aneurysm, Others) & By Region-Forecast (2016-2022)

  • $ 5422
  • Industry report
  • September 2016
  • by Industry ARC

Vascular graft procedures are minimally invasive besides involving repairing vessels from the inside as compared to other conventional vascular surgical procedure.In vascular graft procedures, Catheter-based ...

Global Cardiovascular Disease Market to 2022 - Sanofi and Novartis to Become Market Leaders as Praluent and Entresto Drive Revenue Growth

Global Cardiovascular Disease Market to 2022 - Sanofi and Novartis to Become Market Leaders as Praluent and Entresto Drive Revenue Growth

  • $ 4995
  • Industry report
  • October 2016
  • by GBI Research

Global Cardiovascular Disease Market to 2022 - Sanofi and Novartis to Become Market Leaders as Praluent and Entresto Drive Revenue Growth Summary Cardiovascular disease (CVD) covers a range of difference ...

Global Left Atrial Appendage Closure Market 2017-2021

Global Left Atrial Appendage Closure Market 2017-2021

  • $ 3500
  • Industry report
  • January 2017
  • by Infiniti Research Limited

About Left Atrial Appendage Closure Atrial fibrillation is one of the most common types of arrhythmia and is characterized by fast and irregular heart rhythms. The atria of patients suffering from the ...


ref:plp2014

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.